Objective: the aim of the present study was to assess serum BAFF levels in patients with systemic sclerosis and to correlate it with disease features, treatment received and disease severity.Methods: The present study comprised two groups: Group 1 consisted of Sixty Egyptian patients with SSc, they included 54 female (90%) and 6 male patients (10 %) whose ages ranged from 12-60 years with mean age 38.18 ± 12.06 years. Patients under study included 45 patients (75%) with diagnosis of diffuse SSc and 15 patients (25%) with limited SSc. The disease duration in the study group ranged from 1-18 years with mean duration of 7.85 ± 4.075 years. Group 2 consisted of Twenty five healthy controls, they included 13 female (52%) and 12 males (48%). Their ages ranged from 18-53 years with mean age 34.04 ± 9.24 years.Results: SSc patients showed a statistically significant higher mean serum BAFF level than healthy controls (1100 ± 835.4 versus 546.1 ± 471.1 pg/ml respectively. P= 0.0001). No significant correlations were found between serum BAFF levels and patients ages and disease duration. Statistically significant positive correlations were found between serum BAFF level and the presence of malabsorbtion and episodes of pseudo obstruction (r =0.290, p =0.025). Statistically significant positive correlations were found between serum BAFF level and the patients received MTX (r =0.304, p = 0.018*) however, there was no statistically significant correlation between serum BAFF levels and duration of therapy for MTX (r = -0.118, p =0.468) or cumulative dose of MTX received(r =0.170, p .294) and On comparing between patients received MTX and patients did not receive MTX regarding BAFF a statistically significant difference was detected with p value=0.02*.Conclusion: We can conclude that serum BAFF levels were significantly elevated in patients with SSc irrespective of disease subtype, disease duration or age of patients. This elevation in serum BAFF was significantly related to GIT involvement and MTX therapy.